Novartis Reports Pelacarsen Phase 3 Miss In 8,323 Patients, Leaving Lp(a) Field Open
Michael Torres
Coverage
Biotech Innovation
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Latest
eGenesis Reports Two Pig Kidney Recipients Later Received Human Donor Organs, Easing A Key Xenotransplant Concern
Daniel Cho
Ultragenyx Misses Phase 3 Aspire In Angelman Syndrome, Prompting Expense Reduction Review
Daniel Cho
Teva Reports Phase 2a TEV ’408 Win In Celiac Disease, Extending Its IL-15 Bet
Dr. Priya Nandakumar
Most read
Novartis And Bristol Myers Halt Autoimmune CAR-T Studies After Immune Events, Pressuring A Fast-Moving CD19 Field
Sophia Reynolds
Nature Papers Detail Two Prime Editing Routes For Large DNA Insertions Without Double-Strand Breaks
Michael Torres
Alumis Misses Lupus Phase 2b Endpoints But Advances Envudeucitinib Toward Phase 3 In IFNGS-High SLE
Sophia Reynolds
CRISPR Biotech Scribe Therapeutics Writes a New Chapter With $129M IPO
Emily Carter
More in this beat
Sep 1, 2026Alumis Misses Lupus Phase 2b Endpoints But Advances Envudeucitinib Toward Phase 3 In IFNGS-High SLE
The result is a setback on the headline data, and investors reacted by sending Alumis shares down 54% to below $10 in premarket trading. But the company is treating the trial as a patient-selection problem rather than a target failure, with plans to discuss an IFNGS-focused phase 3 design with the FDA.
Sophia ReynoldsSep 1, 2026Novartis And Bristol Myers Halt Autoimmune CAR-T Studies After Immune Events, Pressuring A Fast-Moving CD19 Field
The two companies paused separate autoimmune CAR-T programs on the same day, each centered on autologous CD19-targeted candidates made with rapid manufacturing platforms. Novartis said its oncology program is not affected, while Bristol Myers said it is reviewing clinical data across zola-cel and aiming to resume enrollment as quickly as possible.
Sophia ReynoldsAug 29, 2026Nature Papers Detail Two Prime Editing Routes For Large DNA Insertions Without Double-Strand Breaks
One paper reports prime assembly, a method that uses prime editors to generate matching 3′-flaps on genomic DNA and donor DNA for precise replacement or insertion. A second paper describes donor-complementary prime editing, or DoPE, which pairs overhang double-stranded DNA donors with engineered guide RNAs to support one-step insertions up to 12.5 kilobases.
Michael Torres
Aug 22, 2026Bonsai Reconstructs Tree-Based Single-Cell Maps, Targeting Distortion In High-Dimensional Data
The paper argues that exploratory analysis in single-cell omics still relies too heavily on visualization methods that require tuning and can be made to match prior expectations. Bonsai’s pitch is different: no tunable parameters, explicit handling of noise and a tree representation intended to preserve high-dimensional distances while supporting downstream analysis through Bonsai-scout.
Daniel Cho
Aug 20, 2026Nutrition Experts Reject Protein Restriction Longevity Claims, Citing 1.2 To 1.6 Grams Guidance
A Cell Press Blue review assembled findings from 350 previously published papers to argue that protein restriction and amino acid restriction may support healthy aging. Experts interviewed by STAT said the paper does not establish a human longevity benefit and could create risk if older adults, sedentary people, or people taking GLP-1 weight loss medicines respond by cutting protein too far.
Daniel Cho
Aug 17, 2026EyePoint Shares Fall 70% After Duravyu Misses Phase 3 BCVA Goal, Raising Stakes For Lucia In Wet AMD
The Lugano trial tested duravyu against aflibercept in about 400 patients with wet age-related macular degeneration and did not meet its main endpoint on best corrected visual acuity after two years. EyePoint highlighted ad hoc and secondary analyses, while Mizuho called the overall result mixed and shifted attention to the upcoming Lucia readout.
Dr. Priya Nandakumar
Aug 13, 2026Definium Said DT120 Cut GAD Symptoms By 5.4 Points In Phase 3, Setting Up A Second Readout Next Month
In the 12-week Voyage study of 214 adults, Definium said DT120 produced a statistically significant placebo-adjusted reduction of 5.4 points from baseline on a clinician-administered anxiety scale, with p < 0.0001. The company now has late-stage wins in generalized anxiety disorder and major depressive disorder, but the commercial and regulatory case in anxiety still depends on whether Panorama confirms the effect next month.
Dr. Alex Morgan
Aug 9, 2026Stanford-Led Tau Study Points Alzheimer’s Drug Efforts Toward Mitochondria
Researchers reported that tau can trigger reverse electron transport in mitochondria, sending electrons in the opposite direction of their usual relay. Blocking that process reversed many harmful effects and improved learning and memory in flies and mice, though whether the same will hold true in people remains unclear.
Emily Carter
Aug 7, 2026Replimune’s Tumultuous Path Leads to FDA Approval for Advanced Melanoma Immunotherapy
Replimune’s Tudriqev immunotherapy overcame substantial regulatory hurdles and a polarized advisory committee process to become a new FDA-approved treatment for advanced melanoma. The approval comes after years of uncertainty and highlights the pivotal role of both scientific evidence and consensus-building within U.S. drug regulation.
Dr. Priya Nandakumar
Aug 6, 2026Takeda’s FDA Approval of New Narcolepsy Drug Ushers in Promising Treatment Era
The U.S. Food and Drug Administration has granted approval to a novel narcolepsy treatment developed by Takeda, representing a significant milestone for the field. This approval is expected to benefit not only narcolepsy patients, but potentially others with related conditions, spotlighting innovations in sleep disorder therapeutics.
Dr. Priya Nandakumar
Aug 4, 2026Pathos AI Expands Oncology Ambitions with Major Cancer Agreements
By signing substantial cancer agreements with global players AstraZeneca and Alphamab Biopharmaceuticals, Pathos AI is moving aggressively into the oncology market. These deals highlight shifting priorities in biotech innovation and the evolving landscape of advanced drug development.
Jonathan Blake
Aug 3, 2026Apnimed’s $192M IPO: Aiming for the First Oral Drug for Sleep Apnea
With funds secured from its IPO, Apnimed sets its sights on regulatory submission and commercial launch of its once-nightly pill, Oxnimbi, for obstructive sleep apnea. This pivotal moment could reshape treatment paradigms for a condition affecting millions, as Oxnimbi approaches a key February 2027 FDA decision.
Dr. Alex MorganOther beats
AI in Drug Discovery
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Biopharmaceutical Industry
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Healthcare Investment
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Medical Technology
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
Regulatory & Policy
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.